Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programmes: Ketamine-peptide conjugate therapeutics - Dominari Holdings

Next Previous
Drug Profile

Research programmes: Ketamine-peptide conjugate therapeutics - Dominari Holdings

Latest Information Update: 31 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AIkido Pharma
  • Developer Dominari Holdings
  • Class Amines; Analgesics; Antidepressants; Antihyperglycaemics; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; General anaesthetics; Ketones; Mood stabilisers; Neuroprotectants; Neuropsychotherapeutics; Obesity therapies; Small molecules
  • Mechanism of Action AMPA receptor agonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Alzheimer's disease

Most Recent Events

  • 23 Jun 2021 AIkido Pharma files for patent protection for the use of ketamine and peptides to treat Alzheimer's disease in USA
  • 23 Jun 2021 Early research in Alzheimer's disease in USA (unspecified route) prior to June 2021
  • 16 Feb 2021 AIkido Pharma in-licenses conjugated peptides technology from Silo Pharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top